{name}
{subtitle}
A Study of Pembrolizumab (MK-3475) in Combination With Belzutifan (MK-6482) and Lenvatinib (MK-7902), or Pembrolizumab/Quavonlimab (MK-1308A) in Combination With Lenvatinib, Versus Pembrolizumab and Lenvatinib, for Treatment of Advanced Clear Cell Renal Cell Carcinoma (MK-6482-012)
city
~76 mi. (Ivano-Frankivsk, Ukraine, +144 more cities)
facility
Ivano-Frankivsk Regional Oncology Clinical Dispensary ( Site 2711), +1 more facility
drug
belzutifan, +3 more drugs
drug type
immunotherapy, +1 more type
Study of Pembrolizumab (MK-3475) Plus Enzalutamide Versus Placebo Plus Enzalutamide in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-3475-641/KEYNOTE-641)
city
~76 mi. (Ivano-Frankivsk, Ukraine, +226 more cities)
facility
Ivano-Frankivsk Regional Hospital-Urology department ( Site 1208), +1 more facility
drug
enzalutamide, +1 more drug
drug type
hormone therapy, +1 more type
Study of Pembrolizumab (MK-3475) Versus Placebo in Combination With Neoadjuvant Chemotherapy & Adjuvant Endocrine Therapy in the Treatment of Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative (ER+/HER2-) Breast Cancer (MK-3475-756/KEYNOTE-756)
city
~76 mi. (Ivano-Frankivsk, Ukraine, +207 more cities)
facility
MI Precarpathian Clinical Oncology Center ( Site 2707)
biomarker
ER Positive, +1 more biomarker
drug
cyclophosphamide, +6 more drugs
drug type
chemotherapy, +3 more types
Coformulation of Pembrolizumab/Vibostolimab (MK-7684A) Versus Pembrolizumab (MK-3475) Monotherapy for Programmed Cell Death 1 Ligand 1 (PD-L1) Positive Metastatic Non-Small Cell Lung Cancer (MK-7684A-003)
city
~76 mi. (Ivano-Frankivsk, Ukraine, +93 more cities)
facility
Communal Non-Commercial Enterprise Prykarpatski Clinical Oncological Center of Ivano-Frankivsk Regio
Pembrolizumab (MK-3475) Versus Placebo Following Surgery and Radiation in Participants With Locally Advanced Cutaneous Squamous Cell Carcinoma (MK-3475-630/KEYNOTE-630)
city
~76 mi. (Ivano-Frankivsk, Ukraine, +137 more cities)
facility
Communal Non-Commercial Enterprise "Prykarpatski Clinical On-Department for daily treated patient (
A Study Evaluating the Efficacy and Safety of Inavolisib + Palbociclib + Fulvestrant vs Placebo + Palbociclib + Fulvestrant in Patients With PIK3CA-Mutant, Hormone Receptor-Positive, Her2-Negative, Locally Advanced or Metastatic Breast Cancer
city
~76 mi. (Ivano-Frankivsk, Ukraine, +186 more cities)
facility
Municipal Institution SubCarpathian Clinical Oncological Centre; Surgical department#2
biomarker
ER Positive, +3 more biomarkers
drug
fulvestrant, +2 more drugs
drug type
hormone therapy, +1 more type
Study of Olaparib (MK-7339) in Combination With Pembrolizumab (MK-3475) in the Treatment of Homologous Recombination Repair Mutation (HRRm) and/or Homologous Recombination Deficiency (HRD)-Positive Advanced Cancer (MK-7339-007/KEYLYNK-007)
city
~76 mi. (Ivano-Frankivsk, Ukraine, +115 more cities)
facility
Communal Non-Commercial Enterprise "Prykarpatski Clinical On-Department for daily treated patient (
biomarker
ATM Loss, +27 more biomarkers
condition
Breast Carcinoma, +2 more conditions
drug
olaparib, +1 more drug
drug type
immunotherapy, +1 more type
A Study of Imlunestrant, Investigator's Choice of Endocrine Therapy, and Imlunestrant Plus Abemaciclib in Participants With ER+, HER2- Advanced Breast Cancer
city
~77 mi. (Uzhgorod, Ukraine, +192 more cities)
facility
Uzhgorod Central City Clinical Hospital
biomarker
ER Positive, +1 more biomarker
drug
abemaciclib, +1 more drug
drug type
hormone therapy, +1 more type
A Study Evaluating the Efficacy and Safety of Giredestrant Combined With Palbociclib Compared With Letrozole Combined With Palbociclib in Participants With Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer (persevERA Breast Cancer)
city
~77 mi. (Uzhgorod, Ukraine, +262 more cities)
facility
Uzhgorod Central City Clinical Hospital
biomarker
ER Positive, +1 more biomarker
drug
giredestrant, +2 more drugs
drug type
hormone therapy, +1 more type
Perioperative Enfortumab Vedotin (EV) Plus Pembrolizumab (MK-3475) Versus Neoadjuvant Chemotherapy for Cisplatin-eligible Muscle Invasive Bladder Cancer (MIBC) (MK-3475-B15/ KEYNOTE-B15 / EV-304)
city
~91 mi. (Przemyśl, Poland, +93 more cities)
facility
Wojewodzki Szpital im. Sw. Ojca Pio w Przemyslu ( Site 1053)
condition
Bladder Carcinoma, +1 more condition
drug
cisplatin, +4 more drugs
drug type
chemotherapy, +3 more types